Robert M. Williams Jr., identified as a ten percent owner of Aveanna Healthcare Holdings, Inc. (NASDAQ: AVAH), has completed a significant reduction in his equity position. The filings indicate that Williams sold common stock valued at approximately $24,030,000. These transactions were finalized on June 30, 2026, marking a notable shift in the ownership structure of the home health care provider.
The divestment involved the disposal of 3,000,000 shares of Aveanna Healthcare Holdings common stock. Each share was sold at a uniform price of $8.01. The execution of these sales was not direct; instead, they were carried out indirectly through several affiliated entities. The specific breakdown of the indirect sales reveals that J.H. Whitney VII, L.P. disposed of 2,419,035 shares. JHW Iliad Holdings LLC sold 525,844 shares, while JHW Iliad Holdings II LLC offloaded 55,121 shares.
The timing and pricing of this sale are particularly notable when viewed against the current market performance of AVAH. The $8.01 execution price sits below the stock's recent trading price of $9.22. Over the preceding twelve months, the stock has experienced a surge of nearly 99%. Despite this recent appreciation, data from InvestingPro suggests that the stock may remain undervalued relative to its calculated Fair Value of $9.65. This valuation metric places Aveanna Healthcare among the list of most undervalued stocks, with a current Price-to-Earnings (P/E) ratio of 7.75. Investors analyzing these figures might consider the comprehensive Pro Research Report, which covers AVAH and over 1,400 other U.S. equities, for deeper valuation insights.
Following the completion of these transactions, Robert M. Williams Jr. no longer holds any direct shares of Aveanna Healthcare Holdings. However, his indirect beneficial ownership remains intact through a network of entities. Post-transaction holdings show that J.H. Whitney VII, L.P. retains 10,112,123 shares. PSA Healthcare Investment Holdings LLC holds 15,523,810 shares, while JHW Iliad Holdings LLC maintains 1,813,795 shares. Additionally, PSA Iliad Holdings LLC holds 1,426,034 shares, and JHW Iliad Holdings II LLC holds 190,130 shares. Williams, who serves as a Managing Member of Equity Partners VII, a Member of Project Iliad, and a Senior Managing Director of Capital Partners, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
The insider sale occurs concurrently with significant corporate developments for Aveanna Healthcare. The company recently completed the acquisition of Family First Holding, LLC for $175.5 million in cash. This strategic move expands Aveanna's operational footprint, as Family First Homecare operates 27 locations across seven states, primarily delivering skilled Private Duty Nursing services. The acquisition has prompted positive reactions from market analysts and rating agencies.
RBC Capital upgraded its stock rating for Aveanna Healthcare to Outperform. The firm cited solid execution on preferred payor relationships and the expanding scale of the platform as key drivers for the upgrade. Simultaneously, Moody's Ratings upgraded the company's corporate family rating from B3 to B2. This credit upgrade highlights a reduction in leverage and improved business performance, reflecting strategic initiatives that have driven business volume growth and enhanced clinical outcomes.
Further strengthening its financial position, Aveanna announced a repricing of its first lien credit facility and revolving credit facility. This restructuring reduces applicable interest rate margins by 50 basis points. The terms include provisions for further interest rate reductions if specific credit ratings are achieved. These financial maneuvers indicate a concerted effort to optimize the company's balance sheet and operational capabilities.
While the corporate fundamentals appear robust with acquisitions and rating upgrades, the large-scale insider sale by a ten percent owner introduces a layer of complexity for investors. The divergence between the $8.01 sale price and the current $9.22 market price, alongside the stock's near-100% annual gain, may suggest differing internal valuations or liquidity strategies. Investors monitoring AVAH must weigh the positive analyst and credit upgrades against the substantial reduction in insider equity holdings.